- Home
- DNTH vs GHY Comparison
DNTH vs GHY Comparison
Compare DNTH & GHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- GHY
- Stock Information
- Founded
- DNTH 2015
- GHY 2012
- Country
- DNTH United States
- GHY United States
- Employees
- DNTH N/A
- GHY N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- GHY Trusts Except Educational Religious and Charitable
- Sector
- DNTH Health Care
- GHY Finance
- Exchange
- DNTH Nasdaq
- GHY Nasdaq
- Market Cap
- DNTH 606.2M
- GHY 548.8M
- IPO Year
- DNTH N/A
- GHY N/A
- Fundamental
- Price
- DNTH $21.50
- GHY $13.02
- Analyst Decision
- DNTH Strong Buy
- GHY
- Analyst Count
- DNTH 8
- GHY 0
- Target Price
- DNTH $53.00
- GHY N/A
- AVG Volume (30 Days)
- DNTH 387.8K
- GHY 184.8K
- Earning Date
- DNTH 08-07-2025
- GHY 01-01-0001
- Dividend Yield
- DNTH N/A
- GHY 10.58%
- EPS Growth
- DNTH N/A
- GHY N/A
- EPS
- DNTH N/A
- GHY N/A
- Revenue
- DNTH $6,524,000.00
- GHY N/A
- Revenue This Year
- DNTH N/A
- GHY N/A
- Revenue Next Year
- DNTH N/A
- GHY N/A
- P/E Ratio
- DNTH N/A
- GHY N/A
- Revenue Growth
- DNTH 102.36
- GHY N/A
- 52 Week Low
- DNTH $13.37
- GHY $10.24
- 52 Week High
- DNTH $32.27
- GHY $11.92
- Technical
- Relative Strength Index (RSI)
- DNTH 61.73
- GHY 42.08
- Support Level
- DNTH $19.90
- GHY $12.75
- Resistance Level
- DNTH $22.49
- GHY $13.00
- Average True Range (ATR)
- DNTH 1.43
- GHY 0.14
- MACD
- DNTH 0.22
- GHY -0.07
- Stochastic Oscillator
- DNTH 64.11
- GHY 27.27
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.